The Guardian | Breast cancer drug everolimus fails to get NICE approval OnMedica The breast cancer drug everolimus (also called Afinitor) is not cost effective for the NHS. This is the recommendation from the National Institute for Health and Care Excellence (NICE) which today refused to give the green-light to everolimus ... Novartis breast cancer drug Afinitor not cost effective for NHS, says draft ... Breast cancer drug ruling Novartis Cancer Drug Fails to Win U.K. Cost Agency's Nod |
